| Name | Title | Contact Details |
|---|---|---|
Aly Ciccio |
Chief Information Officer | Profile |
Theseus is a biopharmaceutical company focused on improving the lives of cancer patients through the discovery, development and commercialization of transformative targeted therapies. Theseus is developing next-generation tyrosine kinase inhibitors (TKIs): "pan-variant" targeted therapies that address all major drug resistance mutations. Theseus` lead product candidate, THE-630, is a pan-variant KIT inhibitor for the treatment of patients with advanced gastrointestinal stromal tumors (GIST), whose cancer has developed resistance to earlier lines of kinase inhibitor therapy. Theseus is also developing a fourth-generation, selective epidermal growth factor receptor (EGFR) inhibitor for C797S-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer (NSCLC).
New Freedoms 90-day reentry program inspires personal growth and accountability while treating substance abuse and other behavioral health needs.
Regulatory and Clinical Research Institute, Inc. is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pearl Health Clinic provides unparalleled treatment to the community of Eastern Idaho and surrounding areas.
Esteve is a Montclair, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.